ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DAWN Day One Biopharmaceuticals Inc

13.40
-0.37 (-2.69%)
May 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,598,046
Bid Price 13.35
Ask Price 14.36
News (1)
Day High 14.17

Low
9.67

52 Week Range

High
18.0699

Day Low 13.32
Company Name Stock Ticker Symbol Market Type
Day One Biopharmaceuticals Inc DAWN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.37 -2.69% 13.40 20:00:00
Open Price Low Price High Price Close Price Prev Close
13.80 13.32 14.17 13.61 13.77
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11,815 1,598,046 $ 13.58 $ 21,695,939 - 9.67 - 18.0699
Last Trade Time Type Quantity Stock Price Currency
17:09:37 formt 102 $ 13.40 USD

Day One Biopharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.19B 87.38M - 0 -188.92M -2.16 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Day One Biopharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DAWN Message Board. Create One! See More Posts on DAWN Message Board See More Message Board Posts

Historical DAWN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.5315.7413.3214.32821,626-2.13-13.72%
1 Month16.3318.069913.3216.32854,823-2.93-17.94%
3 Months16.6618.069913.0215.451,147,924-3.26-19.57%
6 Months11.8218.069911.3015.09812,1871.5813.37%
1 Year12.4718.06999.6713.77905,0780.937.46%
3 Years24.1228.6995.4415.54676,649-10.72-44.44%
5 Years25.0028.6995.4415.57677,583-11.60-46.40%

Day One Biopharmaceuticals Description

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.